

Renalytix plc
("Renalytix" or the "Company")

Result of General Meeting

LONDON and NEW YORK, 31 October 2024Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in [the Circular](#) that contains the Notice of General Meeting, which was sent to the Company's shareholders on 11 October 2024.

The results of the GM are detailed below:

Resolution	In favour		Against		Withheld
	Votes	%	Votes	%	Votes
1	101,692,587	98.73	1,311,467	1.27	41,789
2	102,375,306	99.85	157,078	0.15	513,459
3	101,675,617	98.71	1,326,507	1.29	43,719

For further information, please contact:

Renalytix Plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

Oberon Capital (Joint Broker and Sole Bookrunner)
Mike Seabrook / Nick Lovering / Jessica Cave

Tel: 020 3179 5300

Walbrook PR Limited
Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07407 804 654

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

*The person responsible for making this Announcement on behalf of the Company is
James McCullough, Chief Executive Officer.*

About Renalytix plc

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMWPGBAUUPCGWG